The Clinical, Histological, and Immunohistochemical Features of Bone Metastases: A Review

Ragini Patel [1], Yogendra Sahu [1]

Abstract

Malignant tumors can spread differently, and bone metastasis is a complex process starting years before detection. Cancerous cells adhere in bone marrow spaces, growing undetected. Immunohistochemistry helps diagnose, but up to 30% have unidentified bone metastases despite tests and imaging. This review study introduces a deep learning model (DL-BM) to trace bone metastasis genesis, aiding pathologists when biopsy alone is insufficient. Clinicopathological analysis identifies the main carcinoma site in metastases with unclear origins. Thorough histological examinations of bone biopsies are crucial for suspecting the primary cancer. This review emphasizes using bone degradation indicators to identify bone metastases, tracking disease development, and monitoring treatment response.

Keywords: Deep learning, Bone Metastases, Immunohistochemistry, Bone cancer

Significance | A deep learning model to trace bone metastasis origins, addressing challenges in diagnosis and emphasizing therapeutic implications and monitoring.

*Correspondence: Ragini Patel, Department of Pharmacy, Kalinga University, Naya Raipur, Chhattisgarh, India.
Email: ku.raginipatel@kalingauniversity.ac.in

Editor Md Shamsuddin Sultan Khan And accepted by the Editorial Board Dec 8, 2023 (received for review Nov 8, 2023)

1. Introduction

Bone metastasis is a common occurrence in advanced cases of breast, prostate, and lung cancer, affecting approximately 70% of patients. Clinical symptoms, including bone pain, fractures, spinal cord compression, and elevated blood calcium levels, often characterize metastatic bone cancers. Effectively treating osteoid metastatic cancer (OBMC) requires identifying its origin, with patients displaying elevated levels of specific markers such as SGOT, LDH, uric acid, and alkaline phosphatase. Despite numerous cancer markers lacking diagnostic specificity, this research focuses on determining the primary site of carcinoma in metastasis of uncertain origin over a 20-year span.

Understanding the intricate process of metastasis, wherein malignant cells transition from epithelium to mesenchymal states, is crucial for improving patient outcomes. Despite the inefficiency of metastasis development, it accounts for 90% of cancer-related deaths. Identifying tumor genesis on bone biopsies is essential, and immunohistochemistry analysis plays a pivotal role in identifying the main site of origin. Recent advancements in deep learning technology have furthered medical image analysis, particularly in computational pathology, showcasing the potential of deep learning models to discriminate between different tumor types and locations.

This review investigates the clinicopathological aspects of metastatic bone cancers over two decades, aiming to enhance our understanding of metastasis development and improve diagnostic accuracy through advanced technologies like deep learning and immunohistochemistry.

Cancer often spreads to the bones, especially in advanced cases of breast, prostate, and lung cancer where 70% of patients experience bone metastasis. Symptoms include bone pain, fractures, spinal cord compression, and high blood calcium levels (Papandrianos,

Author Affiliation:
[1] Department of Pharmacy, Kalinga University, Naya Raipur, Chhattisgarh, India.

Please cite this article:
Ragini Patel, Yogendra Sahu. (2023). The Clinical, Histological, and Immunohistochemical Features of Bone Metastases: A Review, Journal of Angiotherapy, 7(2), 1-9, 9403

2207-8843/© 2019 ANGIOTHERAPY, a publication of Eman Research Ltd, Australia.
This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
(https://publishing.emanresearch.org).

N., 2020; Desai, K., 2021). Effectively treating osteoid metastatic cancer (OBMC) requires identifying its source. Patients with bone metastases often have increased SGOT, LDH, uric acid, and alkaline phosphatase levels (elevated in over 50% of cases) (Wang, Z., 2020). Various cancer markers, including glycolic antibodies (CA 15-3, CA 19-9, CA 125), cancer-embryonic antigen (CEA), amino acid alpha (AFP), prostate-specific antigen (PSA), and tissue polypeptide antigen (TPA), lack diagnostic specificity (Li, X., 2020). This research aimed to determine the original site of carcinoma in cases of uncertain origin by studying clinicopathological aspects of metastatic bone cancers over 20 years (Okuma, S., 2020).

Cancer cells metstasize from the original tumor by transitioning from epithelial to mesenchymal, allowing infiltration into nearby tissues and access to veins and lymph nodes through intravasation (Pomykala, K. L., 2020). Despite only 0.02% of cancer cells entering the bloodstream forming clinically detectable metastases, 90% of cancer-related deaths are attributed to metastasis. Deepening our understanding of cellular and molecular pathways associated with metastasis development is crucial for improving patient outcomes (Liu, D., 2020) (Geraets, S. E., 2020).

Neoplasm metastases in bone biopsies indicate either a past carcinoma diagnosis or no history of malignancy. The cancer's focus can be inferred from its morphological structure in histological examinations of bone tissue (Zhao, Z., 2020) (Kanbayashi, Y., 2021). Identifying the primary tumor site involves immunohistochemistry analysis, where antibodies against specific antigens detect tumor cells in unstained tissue slices using a robotic system (Zhang, Y., 2023).

Recent advances in deep learning have led to its widespread use in the medical industry, particularly in medical image analysis. Deep learning's robust learning capacity, excellent transfer performance, and durability make it well-suited for tasks such as tumor diagnosis, categorization, evaluation, metastatic identification, and predictive assessment (Ito, K., 2020) (Diel, I. J., 2022). Its popularity in analyzing digital pathological images has grown, demonstrating benefits and possibilities in computational pathology (Hu, C., 2020) (Masci, G., 2015). Studies also show the model's ability to predict and differentiate between adenocarcinoma and endocrine tumors, as well as determine the presence of tumors in specific locations (Xiong, T., 2023) (Agnoli, C., 2023).

This review represents substantial the advancements in cancer diagnosis and prediction. The use of molecular and immunohistochemical markers significantly enhances the diagnosis of epithelial tumors, particularly in identifying the causes of bone cancer. Secondly, the proposed approach proves to be highly effective when applied to external information, showcasing remarkable flexibility in adapting to diverse staining procedures and imaging equipment. The authors introduce the DL-BM model, designed to predict bone metastasis (BM), which is both end-to-end trainable and demonstrates notable success on the test dataset, emphasizing its efficacy in predicting BM.

2. Literature Review

In cancer research, diverse methodologies and techniques are employed to unravel the complexities of bone metastases. In the study by Yuan et al. (2021), researchers employed mouse xenograft models to investigate the role of carcinoma cell-derived exosomes in living organisms. Exosomes were administered intravenously, revealing that those released from breast cancer cells transmit miR-21 to osteoclasts, consequently promoting bone metastasis. In Xu et al.'s (2021) research, deep sequencing of circRNAs was utilized to identify bone-metastatic circRNAs. Confirmation of these circRNAs in breast cancer tissues, regardless of bone metastases, was achieved through live hybridization. The study demonstrated that eIF4A3-IN-2 therapy reduced circIKBKB expression, effectively blocking bone metastases in breast cancer. Hong et al. (2021) assessed the diagnostic accuracy of a machine learning model trained on CT radiomics (CT-R) to differentiate bone fragments from osteoblastic metastases. Their CT radionics-based random forest algorithm improved diagnostic accuracy, comparable to that of a less-experienced radiologist. Makita et al. (2021) conducted CT scans post-EBRT for bone metastases to evaluate treatment efficacy and identify parameters influencing local control for personalized EBRT. Notably, dose increases above BED10 = 39.0 Gy did not consistently result in improved local control. In a multimodal retrospective qualitative study by Mannavola et al. (2020), individuals with bone metastases from aggressive melanoma were examined for the impact of clinical-pathological parameters and treatment options on complications and survival. Results suggested that the use of bone-targeting agents might reduce the risk of skeletal-related events, warranting further investigation. In Peng et al.'s (2022) study, patient records were analyzed to identify risk factors for bone malignancies in newly diagnosed cases of bladder cancer (PCa), utilizing markers such as increased TPSA, ALP, histological rating, ESR, or tumors in the thoracic lymph nodes for PCa diagnosis in the bones. Finally, Yang et al. (2020) explored the efficacy and safety of CT-guided percutaneous cryoablation for treating painful osteolytic bone metastases, utilizing only local anesthetic in all surgeries (Gan, E. Y., 2015). This approach demonstrated successful and safe treatment for painful osteolytic bone metastases.

3. The Complexities of Bone Metastasis and Advanced Detection Techniques

Despite the immune responses mediated by CD8+ T cells and NK lymphocytes, breast cancer cells manage to access the bloodstream through the peripheral stroma. In contrast, metastatic tumor cells can escape through micro capillaries. Tumor cells and osteoblasts with elevated levels of vascular endothelial growth factor (VEGF) facilitate the establishment of a malignant niche in bone tissue, promoting the formation of new blood vessels. The presence of verbalized malignant cells in bone platelets and circulating tumor cells (CTCs) in the circulatory system serves as indicators of tumor metastases (Maru, D. M., 2008). There is a hypothesis that metastatic tumor cells also inhabit the bone marrow niche, similar to the homing behavior of hematopoietic stem cells (HSCs). During the migratory process, various bone tissue cells, including osteoblasts, blood vessels, and monocytes, release CXC chemokine receptor ligands 12 (CXCL12), contributing to the retention of HSCs or tumor cells in the bone tissue. CXCL12-rich reticular (CAR) cells play a crucial role in the skeletal niche, acting as a protective barrier against tumor cells by surrounding or closely associating with venous tissue cells. Disrupting this pathway's function could potentially prevent the bone metastasis of tumor cells in real-life scenarios. IL-1 from the bone marrow stimulates cancer cell migration to bone by inducing NF-B, entering tumor cells and triggering the development of cancer stem cells (CSCs) through autocrine signals via Wnt.

Figure 1 illustrates the intricate dynamics of osteolytic bone metastases and the RANKL-RANK communication pathway. Various stimuli, including PTHrP, IL-6, IL-8, IL-11, PGE2, and TNF, can prompt osteoblasts and stem cells to produce RANKL. This RANKL then binds to RANK receptors on bones, facilitating the migration and habitation of cells within the microenvironment of the bone marrow. The culmination of this process results in bone resorption, predominantly instigated by mature osteoclasts whose development is influenced by the interplay between RANKL and RANK. Additionally, osteoblasts release OPG, which acts as a safeguard against bone degradation by interfering with the binding of RANK to RANKL. These substances collectively exhibit an osteoprotective effect, diminishing osteoclast activity and impeding the proliferation of tumor cells. Notably, the figure also highlights key molecular components such as VEGF-CXC loop receptors 4, macrophage CXC loop receptors, endocrine hormone-related peptide, cytokines interleukin 6, 8, and 11, testosterone E2, necrosis keratin factor, RANKL, RANK, and osteoprotegerin.

The primary mechanism through which tumor cells induce bone degradation involves the stimulation of osteoclasts, a process influenced by hormones and initiated by cancer cells. Bone deterioration in cancer patients has been associated with inflammatory cytokines such as IL-1, IL-6, IL-8, PTHrP, TNF-alpha, mediator E2, and macrophage intrinsic protein-1 (MIP-1). Particularly, breast cancer cells are implicated in the production of PTHrP, which, in turn, stimulates the generation of osteoclasts. PTHrP achieves this by increasing RANKL levels within cardiovascular and stem cells. Interestingly, while PTHrP expression is notably higher in tumor cells within the connective tissue matrix compared to breastbones and ligaments, its deficiency via the prolactin-STAT5-PTHRP axis is linked to unfavorable clinical outcomes in primary tumors. This challenges the conventional belief that PTHrP protein overexpression is a common occurrence in the disease, leaving the significance of PTHrP protein amplification as a predictive factor in primary tumors open to debate. The circulating segment of PTHrP, known as PTHrP, is discovered to be expressed by both early-stage and aggressive tumor cells, exhibiting unique and potent biological activity. As a systemic biomarker strongly associated with malignancy bone metastasis, PTHrP plays a crucial role in promoting tumor bone metastasis by locally regulating hematopoietic differentiated cells and osteoclast function within the tumor-bone marrow milieu.

Within the TNF protein (TNFR) superfamily, the tandem action of RANKL and RANK governs the formation and digestion of osteoclasts, acting as a crucial transmitter-ligand pair. Following NF-B activation, TNF receptor-associated gene 6 (TRAF6) binds to RANK, playing a pivotal role in the calcium-driven generation of osteoclasts. The initiation of osteoclast development is intricately linked to the transcription factor neuronal factor of activated T cells cytoplasmic 1 (NFATc1), whose initial elevation relies on RANKL-induced activation of nuclear factor B (NF-B) and c-Fos. The sodium-dependent signaling cascade is triggered by the phosphorylation of adapters containing immunoreceptor serine-based activating modules (ITAM), engaging spleen tyrosine (Syk), activating gamma radiation, and mobilizing calcium. The transcranial protein 64 (Tmem64) has been identified as a positive regulator of Ca2+ fluctuations in resorption formation in in vitro-generated osteoclasts. The discovery of specific RANK messages in osteoclasts has led to the use of human IgG2 monoclonal antibody therapies to prevent osteoclast formation, mitigate bone loss in solid tumors or skeletal-related events (SREs), and extend the lives of individuals with malignancies; these antigens may also reduce the risk of developing the condition in those at high risk. The RANKL-RANK axis is intricately linked with immunological function, with RANKL initially identified in the EL40.5 mouse lymphoma cell line. Genomic analysis has identified RANKL as a DC stimulator generated by activated T cells, highlighting its central role in regulating T cell-dendritic cell interactions. The selective stimulation or suppression of immunity by the RANKL-RANK relationship depends on the tissue context and pathology. When osteoclasts breach the inner protective barrier and coating epithelium of a reclining bone, they establish a moisture barrier on

the crystallized bone matrix, leading to its deterioration and calcification. The key limiting factors for collagen matrix breakdown are matrix metalloproteinases (MMPs) and vitamin K, a highly efficient gelatin-soluble cysteine protease.

The recognition of the recurring pattern in bone metastasis has driven the exploration and assessment of novel drugs targeting intricate pathways involved in this process, as illustrated in Figure 2. Effective targeting of RANK/RANKL activity is pivotal for preventing osteolytic bone disorders. Denosumab, a humanized RANKL antibody, is the pioneer in this class, proving more effective in averting bone abnormalities in breast cancer and prostate malignancies spreading to bones compared to ZOL. By mimicking osteoprotegerin (OPG), Denosumab hinders osteoclast survival and bone resorption, disrupting the RANKL/RANK interaction. Denosumab has gained approval for preventing skeletal-related events (SREs) in cancer patients based on positive clinical study outcomes. Recent research highlights AMG161, a Denosumab analog, as capable of inhibiting RANKL signaling and micrometastases' development in bone. Anti-CXCL12 drugs show efficacy in a preventive context, especially when initiated before full tumor development. The CXCL12/CXCR4 pathway activation, identified to suppress VEGFR activity in BMDCs, can be addressed with Cediranib, pan-VEGFR tyrosine inhibitors. Combining anti-CXCL12 therapy with anti-VEGFR treatments yields optimal therapeutic outcomes. These drugs also exhibit promise in treating other cancer types. Given the heightened TGF-β activity in over 50% of breast tumors, TGF-β inhibitors represent a new class of medicines for preventing cancer bone metastases. Preclinical studies emphasize the effectiveness of TGF-β inhibition in curbing tumor growth and metastasis, especially in triple-negative breast malignancies targeting bones. Several TGF-β antagonists are undergoing clinical evaluation, with examples including the antibody 1D11 against TGF-β, the receptor phosphatase inhibitor LY2109761, and the displacing drug BMP7.

The progression of cell replication leading to the formation of metastases is a crucial aspect of bone metastasis, alongside the mechanisms enabling cancer cells to invade and spread to new sites, particularly the skeleton. An imbalance between bone erosion and production, disrupting normal bone growth, has been proposed as a mechanism for bone metastasis. The release of hormones critical for the survival and multiplication of tumor cells occurs with bone loss, originating from substances produced by cartilage-forming cells enclosed in the cartilage matrix, such as TGF-β. TGF-β plays a pivotal role as a growth factor, influencing osteoclastic bone loss, immune response, and bone reconstruction. Both experimental and clinical evidence indicates an amplified TGF-β signaling in cancer. Individuals with bone malignancies from prostate tumors exhibit significantly higher levels of TGF-1 in their plasma. Moreover, metastatic tumor sites in the bone demonstrate Smad-dependent TGF-signaling. Paradoxically, TGF-β may inhibit tumor development at the disease's onset while promoting penetration and bone metastases in later stages.

The activation of osteoclasts is a critical factor in the formation of osteolytic bone metastases. Osteoclasts, cells with multiple nuclei, regulate internal calcium and mineral phosphate levels and originate from hematologic precursors in the multifunctional macrophage/monocyte pathway. These precursors, derived from the bone marrow (BM) and the multifunctional macrophage/monocyte-lineage, circulate and localize at sites of bone remodeling. To initiate the differentiation process, osteoclast precursors must encounter two primary regulatory elements: macrophage colonies and RANKL. Osteoblast-derived RANKL binds to its receptor RANK on the surface of osteoclast precursors, promoting their development into mature osteoclasts through activated signaling networks like mitogen-triggered protein kinases and 3-kinase/Akt. The RANK-RANKL signaling cascade can be inhibited by removing RANKL and the mimic protein bone marrow protein (OPG) produced by osteoblasts. Thus, the balanced interaction between RANKL and OPG determines the growth and development of bones.

Numerous clinical studies advocate for the use of anti-osteoclastic bisphosphonates as a preventive measure against osteoporosis following adjuvant treatment for breast cancer. Research on animals provides direct evidence that bisphosphonates not only inhibit tumor growth but also enhance permeability. Zoledronic acid, a third-generation marrow-targeting bisphosphonate, diminishes bone-responsive function by inhibiting the farnesyl diphosphate enzyme and protein prenylation. Despite its efficacy, post-marketing monitoring of zoledronic acid has revealed uncommon side effects such as renal toxicity, dental bone loss, atypical tibial fractures, and reactive ocular responses. Restorative radiotherapy is often administered to cancer patients with bone metastases, aiming to achieve pain relief, recalcification, stability, nerve compression reduction, and mitigation of neurological effects. Moderate radiotherapy for bone metastases has the overall outcome of alleviating pain (by interfering with biomolecular pain control pathways), halting osteolytic processes, and reducing tumor size. Combining bone-altering agents with radiotherapy enhances the therapeutic effectiveness for bone metastases compared to using bone-modifying agents alone.

Rather than relying on manual feature extraction through traditional Machine Learning (ML) methods, deep learning tools automate the process by autonomously learning intricate features and image-related structural connections. This is achieved by analyzing the inherent data structure across numerous network nodes or slightly preprocessed data. Consequently, deep learning technology empowers individuals without specialized expertise, significantly enhancing the efficiency of image analysis without



Figure 1. Immunohistochemical activity in Bone Metastases



Figure 2. Clinically Inhibiting Bone Metastasis Pathways



Figure 3. Deep learning based Bone Metastases retrospective diagnosis

requiring an expensive feature extraction procedure. The subsequent discussion outlines the application of deep learning in the context of treating primary and secondary bone cancers, as depicted in Figure 3.

Ensuring the creation of a high-quality, standardized training dataset for a deep learning algorithm involves a crucial step: image preparation. Standardizing photos maintains data consistency, enabling comparisons across different equipment and acquisition conditions. To streamline picture mining and analysis, a classification system is employed, superimposing a bounding box over the relevant area in the image. Numerous deep learning algorithms have demonstrated outstanding results in interpreting radiological and pathological images, akin to experienced medical professionals. Radiological images from X-ray, CT, and MRI form the basis for deep learning applications in cancer detection, classification, segmentation, and grading. Techniques such as bone scintigraphy, PET, and spectrum CT, combined with deep learning, enhance the detection of bone metastases. Deep learning models applied to H&E-stained clinical images reveal tumor histopathology, aiding in tumor categorization, prognostic estimation, and treatment guidance. For bone tumor evaluation, CT and MRI provide richer radiographic data, with various deep learning methods developed for categorization and segmentation. Despite challenges, such as the temporal and anatomical differences of osteosarcoma segments on CT, automated segmentation using supervised convolutional networks shows promise. Noninvasive approaches utilizing deep learning for detecting chemotherapy-induced tumor apoptosis are essential for improving the accuracy of clinical assessments of chemotherapeutic sensitivity. Predicting clinical diagnosis and therapeutic response can be achieved through immunohistochemistry (IHC) for specific biomarkers and the histology of tumors as indicated by digitized H&E-stained cell images, which have become the gold standard in recent years.

This below algorithm highlights the challenges associated with detecting dispersed foci of bone metastatic cancer in imaging, particularly in compressed and twisted bone tissues. The proposed technique offers the potential to enhance classification precision and annotation productivity. The model, from feature extractors to attention-pooling networks, can be trained in parallel, with attention scores calculated based on patch vectors and a weighted attentiveness system. The attention scores influence the overall regional predictions. The classification layer, incorporating gender information, generates final geographical probabilities.

For individual case stage categorization, pathologists prioritize individual cases over broad predictions. The contribution of each LR to the overall case stage categorization is considered equal. The discussion introduces the concept of LR origin likelihood, determined by weighting all possible origins and taking the mean. The probability at a specific instance stage (R_case) is calculated based on the accumulated probabilities of each LR.

The model shows the investigation of factors affecting accuracy, such as the number of regions in an LR, the algorithm's framework, and gender addition. The structured discussion emphasizes that bone metastasis is not a random occurrence but a coordinated process involving cancer cell evasion, infiltration into bones, and the interplay between malignancy and cartilage, resulting in bone destruction. The importance of growth factors produced by osteoblasts in bone metastasis is highlighted, emphasizing the disrupted balance between bone erosion and formation in the metastatic process. Overall, the discussion provides a comprehensive overview of the proposed technique and its implications for understanding and detecting bone metastases.

The whole model, from feature extractors to attention-pooling networks, can be trained in parallel throughout the training process. training process. The a^{th} patch's vector of traits $(a = 1, 2, \ldots, M)$ is denoted by s_a. The significance of the a^{th} patch in making a regional prediction is represented by its attention score k_a, which is calculated in Equation (1):

$$k_a = \frac{\exp\left(s_k\left(\tan d(Q_k s_a) \odot \sigma(W_k s_a)\right)\right)}{\sum_{y=1}^{M} \exp\left(s_k\left(\tan d(Q_k s_y) \odot \sigma(W_k s_y)\right)\right)} \quad (1)$$

When L = 769 and D = 1025, the dimensions Q_k and $W_k \in \mathbb{R}^{L \times D}$ are the same. The feature depth for every patch is denoted here by the letter D. The weighted factor $W_k \in \mathbb{R}^{1 \times 769}$ in the attentiveness system is separate from the others. A LR's representation matrix may be written as $c_{ero} \in \mathbb{R}^{1 \times D}$ in Equation (2).

$$c_{ero} = \sum_{a=1}^{M} k_a s_a \quad (2)$$

The patient's binary-encoded gender is appended to c_{ero} to create a new vector $\acute{c}_{ero} \in \mathbb{R}^{1 \times (D+1)}$. A classification layer receives $\acute{c}_{ero}$ as input and returns R_{ero} as the final geographical probabilities, when treating patients, pathologists focus more on individual cases than broad predictions. It is believed that each LR contributed equally to the overall case stage categorization. To determine which LR origin was most likely, then weighted all of the possible ones and used the mean. R_{case} represents the probability at the particular instance stage in Equation (3).

$$R_{case} = \frac{1}{N}\left(\sum_{1}^{N} R_{ero}^{n}\right) \quad (3)$$

The probability of the n-th LR is denoted by R_{ero}^{n}, where N is the total number of images in the instance.

4. Challenges and Therapeutic Prospects

Bone metastases (BMs) are a prevalent occurrence in various cancers, significantly impacting both the quality of life and survival of affected individuals. While extensive prospective studies involving cancers prone to metastasize to bones, such as breast, prostate, lung, and renal cancers, provide valuable insights into therapeutic approaches for bone disorders (BD), a distinct, proven procedure for treating BMs, especially in comparison to tumors with a lower osteotropic tendency, remains elusive. Novel drugs like cilengitide have shown limited promise for widespread clinical implementation. Notably, the impact of BD in melanoma and potential treatment methods, such as the use of radiation therapy (RT) or bone-targeting agents (BTA), has been minimally explored.

A detailed examination of organs and lymphocytes under the magnifying lens is crucial in histology for diagnosing and researching tissue disorders. Histopathologists, responsible for tissue diagnosis, play a vital role in assisting doctors in patient care management. The dataset provided for categorization consists of histopathological images sourced from www.kaggle.com. These micrographs capture hematite and eosin (H&E) stained lymph nodes on glass slides, essential for understanding and classifying tissue abnormalities.

a) Clinical reaction to eliminate malignant cells:

Figure 4 illustrates metastatic bone formation characterized by the expression of CXCR4, MMP-1, FGF5, CTGF, IL-11, OPN, follistatin, and peptides 1. This process is the result of specific selections and the enhancement of existing biological communities. Identifying these genes and their associated signaling pathways holds the potential to reveal therapeutic targets. Experimental evidence suggests that silencing CXCR4 gene expression using short intervening RNAs can inhibit cancer cell invasion. In animal studies, this intervention prevents metastasis, while anti-CXCR4 agents significantly reduce the size of bone metastatic tumors in prostate cancer. Metastatic cells, which are resilient to the apoptosis induced by anticancer drugs, utilize signaling pathways involving nutrients and mediators. Thus, inhibiting these longevity factors in bones (TGF, IGF, IL-6, FGF, ET-1, among others) may enhance the susceptibility of cancer cells to radiation therapy.

b) Impact of Immunohistochemical Classification:

Figure 5 illustrates the reactivity of osteosarcomas to vimentin, but the lack of distinctive markers poses challenges for immunohistochemical classification. While anti-osteonectin antibodies exhibit limited reactivity and may interact with cell types other than osteoblasts and osteocytes, anti-osteocalcin antibodies offer greater specificity, reacting solely with osteocytes in adult bones and exhibiting positive antibodies in 66.6% of cases with low grades. In high-grade unclassified osteosarcomas, bone marrow antibodies show significantly weaker reactions, suggesting reduced sensitivity with increased neoplastic differentiation. Nevertheless, the immunohistochemistry panel aids in identifying the anatomical origin of osteosarcomas and distinguishing them from other mesenchymal, epithelial, and hematological tumors that may also involve bone marrow centers.

c) Performance of the proposed:

Figure 6 illustrates the effort to enhance the ability to predict the progression of bone metastatic cancer by utilizing these images to train a feature extraction network. The training process encounters significant delays when dealing with more than 55 patches in a training set. Notably, a substantial improvement in the performance of the deep convolutional layer was observed by increasing the number of lines and expanding the receptive field. This enhancement is crucial as it allows the consideration of macroscopic features of cells, including replication and nuclear dimensions, as well as intricate details of tumors, such as nest structure, endocrine organization, filter substance, eliminate consistency, and necrosis. A broader receptive area enables the extraction of more detailed information about tissues, facilitating the transfer of abnormal image characteristics to higher qualities and handling complex categorization tasks with larger streams and longer modules.

5. Conclusion

In conclusion, the investigation into bone metastasis provides a crucial understanding of cancer cells' affinity for bone and opens avenues for innovative treatments to mitigate tumor mortality. The intricate interplay between tumor cells and the vertebral matrix, particularly through the RANK/RANKL signaling system, unveils potential therapeutic targets for skeletal tumors. The identification of specific genes associated with invasion and metastasis offers the prospect of personalized treatment strategies. Blood markers linked to high metastatic risk present opportunities for tailored therapies, and direct targeting of tumor cells in cartilage tissue holds promise for improving antitumor treatment efficacy. Despite limitations in the study, such as a short follow-up period and retrospective data collection, ongoing research instills hope for advancements in treating challenging bone metastases.

Author Contributions

R.P. and Y.S. conceptualized, wrote, and reviewed the article.

Acknowledgment

None declared.

Competing financial interests

The authors have no conflict of interest.

References

Agnoli, C., Sabattini, S., Ubiali, A., Battisti, E., Rossi, F., Diana, A., ... & Marconato, L. (2023). A retrospective study on bone metastasis in dogs with advanced-stage solid cancer. Journal of Small Animal Practice.

Desai, K., Brown, L., Wei, W., Tucker, M., Kao, C., Kinsey, E., ... & Ornstein, M. C. (2021). A multi-institutional, retrospective analysis of patients with metastatic renal cell carcinoma to bone treated with combination ipilimumab and nivolumab. Targeted oncology, 16(5), 633-642.

Diel, I. J., Greil, R., Janssen, J., Kluike, C. W., Behera, B., Abbasi, A., ... & Haslbauer, F. (2022). Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study. Supportive Care in Cancer, 30(11), 9267-9278.

Gan, E. Y., Chio, M. T. W., & Tan, W. P. (2015). A retrospective review of cutaneous metastases at the N ational S kin C entre S ingapore. Australasian Journal of Dermatology, 56(1), 1-6.

Geraets, S. E., Bos, P. K., & van der Stok, J. (2020). Preoperative embolization in surgical treatment of long bone metastasis: a systematic literature review. EFORT Open Reviews, 5(1), 17.

Hong, J. H., Jung, J. Y., Jo, A., Nam, Y., Pak, S., Lee, S. Y., ... & Kim, S. (2021). Development and validation of a radiomics model for differentiating bone islands and osteoblastic bone metastases at abdominal CT. Radiology, 299(3), 626-632.

https://www.kaggle.com/code/akarshu121/cancer-detection-with-cnn-for-beginners

Hu, C., Yang, J., Huang, Z., Liu, C., Lin, Y., Tong, Y., ... & Zhao, C. L. (2020). Diagnostic and prognostic nomograms for bone metastasis in hepatocellular carcinoma. BMC cancer, 20, 1-11.

Ito, K., Yamaguchi, T., Ogawa, H., Nakajima, Y., & Karasawa, K. (2020). Stereotactic body radiotherapy for bone metastases in patients with colorectal cancer. Japanese Journal of Clinical Oncology, 50(12), 1442-1446.

Kanbayashi, Y., Sakaguchi, K., Hongo, F., Ishikawa, T., Tabuchi, Y., Ukimura, O., ... & Taguchi, T. (2021). Predictors for development of denosumab-induced hypocalcaemia in cancer patients with bone metastases determined by ordered logistic regression analysis. Scientific Reports, 11(1), 978.

Li, X., Wang, L., Chen, S., Zhou, F., Zhao, J., Zhao, W., & Su, C. (2020). Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Thoracic Cancer, 11(10), 2812-2819.

Liu, D., Wu, J., Lin, C., Andriani, L., Ding, S., Shen, K., & Zhu, L. (2020). Breast subtypes and prognosis of breast cancer patients with initial bone metastasis: a population-based study. Frontiers in oncology, 10, 580112.

Makita, K., Hamamoto, Y., Kanzaki, H., Kataoka, M., Yamamoto, S., Nagasaki, K., ... & Kido, T. (2021). Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study. Radiation Oncology, 16, 1-8.

Mannavola, F., Mandala, M., Todisco, A., Sileni, V. C., Palla, M., Minisini, A. M., ... & Tucci, M. (2020). An Italian retrospective survey on bone metastasis in melanoma: impact of immunotherapy and radiotherapy on survival. Frontiers in Oncology, 10, 1652.

Maru, D. M., Khurana, H., Rashid, A., Correa, A. M., Anandasabapathy, S., Krishnan, S., ... & Hofstetter, W. L. (2008). Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. The American journal of surgical pathology, 32(9), 1404-1411.

Masci, G., Caruso, M., Caruso, F., Salvini, P., Carnaghi, C., Giordano, L., ... & Santoro, A. (2015). Clinicopathological and immunohistochemical characteristics in male breast cancer: a retrospective case series. The oncologist, 20(6), 586-592.

Okuma, S., Matsuda, Y., Nariai, Y., Karino, M., Suzuki, R., & Kanno, T. (2020). A retrospective observational study of risk factors for denosumab-related osteonecrosis of the jaw in patients with bone metastases from solid cancers. Cancers, 12(5), 1209.

Papandrianos, N., Papageorgiou, E. I., & Anagnostis, A. (2020). Development of convolutional neural networks to identify bone metastasis for prostate cancer patients in bone scintigraphy. Annals of Nuclear Medicine, 34, 824-832.

Peng, C., Juan, C., Mao, W., Jinghe, Y., & Renli, T. (2022). Retrospective analysis of risk factors for bone metastasis in newly diagnosed prostate cancer patients. European Review for Medical & Pharmacological Sciences, 26(11).

Pomykala, K. L., Czernin, J., Grogan, T. R., Armstrong, W. R., Williams, J., & Calais, J. (2020). Total-body 68Ga-PSMA-11 PET/CT for bone metastasis detection in prostate cancer patients: Potential impact on bone scan guidelines. Journal of Nuclear Medicine, 61(3), 405-411.

Wang, Z., Wang, H., Ding, X., Chen, X., & Shen, K. (2020). A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer. Therapeutic advances in medical oncology, 12, 1758835920932674.

Xiong, T., Jiang, M., Ye, X., Zhu, G., Cao, F., Cui, Y., ... & Niu, Y. (2023). Skull metastasis is a poor prognostic factor for prostate cancer patients with bone metastasis: a retrospective study based on a Chinese population. BMC urology, 23(1), 1-6.

Xu, Y., Zhang, S., Liao, X., Li, M., Chen, S., Li, X., ... & Li, J. (2021). Circular RNA circIKBKB promotes breast cancer bone metastasis through sustaining NF-κB/bone remodeling factors signaling. Molecular Cancer, 20(1), 1-18.

Yang, Y., Li, Y., Wu, Y., Qiu, S., Liu, C., Wang, Q., ... & Du, D. (2020). Retrospective analysis of CT-guided percutaneous cryoablation for treatment of painful osteolytic bone metastasis. Cryobiology, 92, 203-207.

Yuan, X., Qian, N., Ling, S., Li, Y., Sun, W., Li, J., ... & Li, Y. (2021). Breast cancer exosomes contribute to pre-metastatic niche formation and promote bone metastasis of tumor cells. Theranostics, 11(3), 1429.

Zhang, Y., Wang, J., Ding, L., Zheng, Y., Wu, C., Wang, K., ... & Ge, P. (2023). Development and validation of a novel risk model in newly diagnosed de novo bone metastatic prostate cancer (M1b): a retrospective study. PeerJ, 11, e14615.

Zhao, Z., Pi, Y., Jiang, L., Xiang, Y., Wei, J., Yang, P., ... & Cai, H. (2020). Deep neural network based artificial intelligence assisted diagnosis of bone scintigraphy for cancer bone metastasis. Scientific reports, 10(1), 17046.